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Abstract. Liver transaminase elevations after treatment inmalaria volunteer infection studies (VISs) have raised safety
concerns.We investigated transaminase elevations from two humanPlasmodium vivaxVISswhere subjectswere treated
with chloroquine (n=24) or artefenomel (n=8) andcompared themwith studies inThailand (n=41) andMalaysia (n=76). In
the VISs, alanine transaminase (ALT) increased to ³ 2.5 × upper limit of normal (ULN) in 11/32 (34%) volunteers, peaking
5–8 days posttreatment. Transaminase elevations were asymptomatic, were not associated with elevated bilirubin, and
resolved by day 42. The risk of an ALT ³ 2.5 × ULN increasedmore than 4-fold (odds ratio [OR] 4.28; 95%CI: 1.26–14.59;
P = 0.02) for every log10 increase in the parasite clearance burden (PCB), defined as the log-fold reduction in parasitemia
24 hours post-treatment. Although an elevated ALT ³ 2.5 × ULN was more common after artefenomel than after chlo-
roquine (5/8 [63%] versus 6/24 [25%]; OR 5.0; 95% CI: 0.91–27.47; P = 0.06), this risk disappeared when corrected for
parasite clearanceburden (PCB). PeakALTalso correlatedwith peakC-reactive protein (R=0.44;P=0.012). Elevations in
ALT (³ 2.5 × ULN) were less common in malaria-endemic settings, occurring in 1/41 (2.5%) Thai patients treated with
artefenomel, and in none of 76 Malaysians treated with chloroquine or artemisinin combination therapy. Post-treatment
transaminase elevations are common in experimentalP. vivax infection but do not appear to impact on participant safety.
Although the mechanism of these changes remains uncertain, host inflammatory response to parasite clearance may be
contributory.
INTRODUCTION
Liver enzymeelevations havebeen recently reported in both
Plasmodium falciparum1 and Plasmodium vivax2 malaria vol-
unteer infection studies (VISs), otherwise known as controlled
human malaria infection studies. These studies entail in-
tentional infection of healthy volunteers with Plasmodium
parasites, bymosquito bites,3 direct injection of sporozoites,4
or by intravenous inoculation of parasitized red blood cells.2,5
The latter bypasses the liver stage of infection and is referred
to as the induced blood-stage malaria (IBSM) model. Volun-
teer infection studies are increasingly being used to evaluate
antimalarial vaccine and drug candidates4,6 and have been
established for P. falciparum,7 P. vivax,2,8 and Plasmodium
malariae.5 However, recent reports of elevated liver enzymes
post-treatment have raised concerns related to the safety of
healthy volunteers and have the potential to impede antima-
larial drug development because of difficulties distinguishing
drug-induced liver injury (DILI) from the effect of malaria.
DILI is the most common cause of cessation of develop-
ment of a new chemical entity (NCE) for safety reasons.9 DILI
can be divided into intrinsic injury, which is related to a direct
drug effect and is typically dose dependent, and idiosyncratic
injury, which occurs in specific susceptible individuals. The
latter is typically not dose related and is, therefore, more dif-
ficult to predict. Most drugs that cause severe DILI do so in-
frequently, typically requiring at least a few thousand exposed
subjects to demonstrate the effect.9 Therefore, close attention
must be paid to lower degrees of DILI during preclinical and
clinical drug development. Hence, liver function test (LFT)
abnormalities must be carefully evaluated during malaria VISs
where an NCE is under development. Incorrect attribution of
liver injury to an NCE can lead to cessation of further devel-
opment; conversely, attributing the liver injury solely tomalaria
may risk failure to detect DILI. Currently, there is no reliable
biomarker to distinguish DILI from other causes of liver injury.
Therefore, better understanding of the factors associatedwith
post-treatment LFT abnormalities in malaria VISs is required.
Malaria hepatopathy is a common phenomenon in natural
malaria infection, occurring in both P. falciparum and P. vivax
infections. It is defined as a bilirubin > 2.5 × upper limit of
normal (ULN) and an increase in transaminase > 3 × ULN.
TheseLFTelevationsgenerallypeakaroundthe timeofdiagnosis
and before commencement of antimalarial chemotherapy.10–14
By contrast, a distinct pattern of LFT abnormality has been re-
ported in P. falciparum1 and P. vivax VISs.2 This is characterized
by transaminase elevation without an increase in bilirubin, with a
peak observed approximately 2–6 days posttreatment.15–17 Sim-
ilar changes have been described in natural P. falciparum18,19and
P. vivax infections,18 although they have been reported less
commonly thanmalariahepatopathy.Thedifferencesbetweenthe
malaria hepatopathy and post-treatment LFT changes suggest
that they may be mediated by different mechanisms. The
mechanisms underlying post-treatment liver injury are in-
completely understood. Possible contributing factors in-
clude an increased inflammatory response following malaria
treatment, release of hepatotoxic iron products from red
cells, oxidative damage, and, potentially, a hepatotoxic ef-
fect of antimalarial drugs or other concomitant drug treatment
(including acetaminophen).15
The aim of our study was to describe in detail the LFT ab-
normalities observed in two P. vivax IBSM studies and to eval-
uate possible risk factors. One of these studies entailed
treatment with the investigational antimalarial artefenomel, and
the other with the licensed drug chloroquine. Neither artefeno-
mel nor chloroquine has been associated with hepatotoxicity
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when used as monotherapy in standard dose regimens in
healthy adults20–23 or in children with malaria.24 However, post-
treatment LFT abnormalities have been reported in malaria pa-
tients treated with artefenomel in malaria-endemic settings.25,26
We compared findings from the P. vivax VISs with data from a
published phase IIA open-label study of artefenomel treatment of
malaria in Thailand25 and from studies of chloroquine or artemi-
sinin combination therapy conducted in Malaysia.27,28
MATERIALS AND METHODS
Subjects and study design. Data for the P. vivax IBSM
analysis were obtained from 32 malaria-naive subjects who
participated in two clinical trials at the Queensland Institute of
Medical Research (QIMR)Berghofer betweenMarch 2016 and
April 2017. The results of one of these studies, which used
chloroquine29 and artefenomel30 as antimalarial treatment
have been published. An article describing the results of the
other study (NCT02573857), which used the experimental
compound artefenomel as antimalarial treatment, is currently
under review. Key details are included in Table 1. Subjects
were all healthy adults aged between 18 and 55 years. Sub-
jects with a history or clinical signs of liver disease were ex-
cluded. All subjects hadalanine transaminase (ALT), aspartate
transaminase (AST), and total bilirubin levels within the normal
rangeatbaseline. Subjectswere inoculated intravenouslywith
theP. vivax isolate HMP-013.29 In the artefenomel study, eight
subjects were treated with a single 200 mg dose of the drug
10 days post-inoculation.30 Data from previous studies had
indicated that a 200 mg dose would be subcurative,31 and as
expected, 7/8 subjects had recrudescent parasitemia; they
subsequently received a standard course of artemether/
lumefantrine on day 21–28. In the chloroquine study, 24
subjects were treated with a standard 3-day course of chlo-
roquine, totaling 25mg/kg, beginningonday8 (n=8subjects),
day 9 (n = 1 subject), or day 10 (n = 15 subjects). All subjects in
the chloroquine study cleared parasites.
Individual patient-level biochemistry results were made
available from a previously published phase IIA open-label
study.25 This study had enrolled patients at the Hospital for
Tropical Diseases in Bangkok and Shoklo Malaria Research
Unit located on the northwestern border of Thailand between
October 2010 andMay 2012. Data from 41 adult patients with
microscopically confirmed P. vivax mono- (n = 40) or mixed
infection (n = 1) were analyzed. Liver function tests were mea-
sured before artefenomel treatment, 4 hours post-treatment,
and on days 1, 2, and 7.
In the study undertaken in Malaysia, adults and children > 1
year of agewithP. vivaxmonoinfectionwere enrolled fromJuly
2013 to November 2015 as part of a randomized controlled
trial27 or a prospective observational study,28 both conducted
at KotaMarudu, Kudat, and Pitas district hospitals. LFTswere
undertaken on samples from 85 patients. All had ALT levels
tested on days 0 (before treatment) and 7, whereas AST was
measured in 19/85 and 85/85 subjects on day 0 and day 7,
respectively. Total bilirubin levels were tested in 76/85 sub-
jects on day 0 and 85/85 subjects on day 7.
Parasitemia measurements. Parasitemia was measured
before treatment and at multiple time points throughout the
VISs by 18S-qPCR32 and analyzed on the log10 scale. The
parasite clearance rate was reported using the parasite
clearance half-life (PCt1/2) in hours, as previously reported.
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For the artefenomel VISs, the PCt1/2 was censored at par-
asitemia nadir, ∼36 hours post-treatment, and before re-
crudescence. Although chloroquine was administered over
3 days, the initial parasite PCt1/2 was assumed to represent a
continuous pharmacodynamic effect.29
A variable was calculated to capture the biomass of para-
sites cleared in the first 24 hours after treatment. This variable,
termed as the parasite clearance burden (PCBpeak-24) was
calculated by subtracting the parasitemia at 24 hours post-
treatment initiation from the peak parasitemia on the log10
scale and is reported as a log-fold change. The 24-hour cutoff
was selected because most parasites were cleared over this in-
terval, yetparasitemiaremainedmeasurable.Thepeakparasitemia
occurred at or around the time of treatment for all subjects.
Markers of host response. Temperature, malaria clinical
score, and C-reactive protein (CRP) were measured as
markers of host response. Temperatures < 37.5C were
considered normal. The malaria clinical score has been de-
velopedasa tool for assessing theclinical severity ofmalaria in
IBSM studies34 and forms part of the criteria for treatment
initiation (Supplemental Material). The maximum temperature
and clinical scores were taken from values recorded within
3 days pre- and post-treatment to ensure the changes were
due tomalaria infection and treatment andnot to analternative
cause.
Laboratory parameters. LFT and hematology results from
the IBSM subjects were taken at screening, pre-inoculation,
pre-treatment, 72 hours post-treatment, 5–8 days post-
treatment, and at the end of study (EOS). CRP levels were
retrospectively measured on a total of 31 stored plasma and
16 stored serum samples in the artefenomel cohort, and 62
stored plasma and serum samples in the chloroquine cohorts.
TABLE 1
Induced blood-stage malaria clinical trials details
Drug Artefenomel Chloroquine
Cohort (n) Artefenomel (8) Chloroquine C1 (8) Chloroquine C2a (6)† Chloroquine
C2b (2)†
Chloroquine C3 (8)
Inoculation dose size
(parasites)
524,000 720,000 722,000 740,000 782,000
Treatment regimen Single dose 200 mg 3 Days* 3 Days* 3 Days* 3 Days*
Day of treatment
post-inoculation
Day 10 Day 8 Day 10 (one subject
treated on day 9)
Day 10 Day 10
Acetaminophen and/or
ibuprofen use
Allowed both Allowed both, encouraged
ibuprofen only, and only
reported ibuprofen use
Ibuprofen Ibuprofen Acetaminophen
* Three-day standard oral curative treatment regimen dosed on a weight basis to a total of ∼25 mg/kg.
†Cohorts 2a and 2b were combined into chloroquine cohort C2 for the statistical analysis as the conduct and characteristics of the cohorts were identical apart from the inoculum dose.
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Additional CRP results were available from tests undertaken
for clinical assessments. The peak ALT level was assessed as
the primary measurement of hepatocyte injury because of its
greater liver specificity than AST.35 Peak ALTwas categorized
into ³ 2.5 × ULN and < 2.5 × ULN (ULN = 40 IU/L for males and
30 IU/L for females) in line with the World Health Organization
guidelines.36
Statistical analysis. Data were analysed using Stata v.15
(StataCorp 2017, College Station, TX),37 and figures were
produced using GraphPad Prism v.8, San Diego, CA.38 De-
scriptive statistics of frequency and percentagewere given for
categorical measures, and continuous variables were pre-
sented asmean and 95%CI or median and interquartile range
(IQR), depending on whether the variable was normally dis-
tributed or not. For the VIS participants, maximum and mini-
mum values for all parameters (LFTs, inflammatory, lactate
dehydrogenase [LDH], and parasitemia) were identified from
inoculation to drug treatment and from inoculation to the EOS.
Correlations between continuous variables were assessed by
Pearson’s correlation of log10-transformed data. Logistic re-
gression analysis was used to test for associations between
explanatory parameters and peak ALT ³ 2.5 × ULN. A fixed
cohort effect was added to the regression models to account
for inherent differences between cohorts. The Mann–Whitney
test was used to assess for difference in ALT values between
the two drug treatments.
A backward stepwise regression was used to create two
multivariable logistic models for predictors of developing a
peak ALT ³ 2.5 × ULN. Any variable that was significant (P <
0.05) in the univariate logistic regression was included in the
backwardstepwise regression. In the firstmultivariablemodel,
the parasite clearance rate was forcibly retained into the final
model; in the second multivariable model, the PCB was in-
cluded. For the Thailand and Malaysia datasets, continuous
measures were described using mean (95% CI), and paired t-
tests on the log10 scale of the measure were used to test the
differences in LFT results between day 0 (pre-treatment for
Thailand artefenomel) and day 7.
Review of subject-level data. The corresponding author
reviewed the source documents of all 32 subjects involved in
the P. vivax IBSM studies to exclude an alternative diagnosis
such as alcohol consumption and to evaluate concomitant
medication use such as acetaminophen.
RESULTS
Volunteer infection studies. All eight subjects enrolled in
the artefenomel study were male compared with a more even
gender ratio in the chloroquine study where 13/24 (54%) of
subjects were males. There was no difference in the age of
subjects recruited in the artefenomel and chloroquine studies
(median [IQR] 23.5 [22–25.8] years and 24.5 [20–30] years,
respectively).
Liver function test abnormalities. Following antimalarial
treatment, an ALT ³ 2.5 × ULN occurred in 11/32 (34%) sub-
jects. Alanine transaminase elevations generally exceeded
AST (correlation peak ALT to peak AST R = 0.99; P < 0.001).
Levels typically began to increase 3 days after treatment,
peaking between days 5 and 8 after treatment and resolving
between day 11 and day 32 after treatment (Figure 1). The
highest ALT observed was 632 IU/L (15.8 × ULN), occurring
6 days post-treatment. All subjects remained clinically well.
There was no relationship between age or gender and LFT
elevations. No volunteer had significant elevations in alkaline
phosphatase or bilirubin, and Hy’s law was not invoked.
Gamma glutamyl transferase was measured in the artefenomel-
treated subjects only; all results were within the normal range.
Creatine kinase was measured in three artefenomel-treated
subjects and one chloroquine-treated subject at or within
3 days of the peak ALT; all were within normal range. Mild
elevations in LDH of up to 1.6 × ULN were observed in 19/32
subjects. Elevations in CRP levels were common and typi-
cally peaked at 2–3 days post-treatment. Peak ALT occurred
before recrudescence of parasitemia in subjects treated with
artefenomel.
The peak ALT was greater among the eight subjects ad-
ministered with artefenomel (median 5.3 [IQR: 2.2–9.1] × ULN)
than that among the 24 subjects who were given chloroquine
(1.0 [IQR: 0.8–2.5] × ULN; P = 0.002) (Figure 2). Likewise, a
greater proportion of subjects in the artefenomel group had a
peak ALT of ³ 2.5 × ULN (5/8 [63%] versus 6/24 [25%]; odds
ratio [OR] 5.0; 95% CI: 0.91–27.47; P = 0.064).
Parasite measures. Peak parasitemia was associated with
peak ALT (R= 0.39;P= 0.027), with a nonsignificant trend also
observed between peak parasitemia and risk of developing
ALT ³ 2.5 × ULN (OR 3.72; 95% CI: 0.77–18.03; P = 0.10;
Table 3). No relationship between PCt1/2 and ALT elevations
was observed (Table 3).
ThePCB (Table3)wasasignificant risk factor for developing
a peak ALT of ³ 2.5 × ULN, with an OR of 4.28 (95% CI:
1.26–14.59; P = 0.020) for a one log10 increase in PCB. A
significant correlation between log10 peak ALT and log10 PCB
(R = 0.48; P = 0.005; Supplemental Figure 1) was also ob-
served. In keeping with its more rapid antimalarial effect, the
PCB was higher in the artefenomel-treated subjects than that
in chloroquine-treated subjects (median 2.18 [IQR: 2.13–2.37]
versus 0.95 [IQR: 0.71–1.22]; P < 0.001; Table 2).
Markers of inflammation and other laboratory parameters.
There was an association between CRP and the likelihood of
ALT elevation: with each increase in the maximum CRP by 4
mg/L (ULN = 4 mg/L), the likelihood of a subject developing
peak ALT ³ 2 × ULN increased by 1.43-fold (95% CI:
1.10–1.86);P=0.008, Table 3. Likewise, thepeakCRP (×ULN)
was associated with peak ALT (R = 0.44; P = 0.012;
Supplemental Table 8).
Multivariable analysis. On multivariable analysis, peak CRP
remained a significant risk factor for developing an ALT ³ 2.5 ×
ULN after controlling for the PCB but not after controlling for
the cohort effect. After controlling for the PCB, artefenomel
drug treatment no longer predicted the development of peak
ALT ³ 2.5 × ULN (OR 5.0 [95% CI: 0.91–27.47; P = 0.064] to
0.84 [95% CI: 0.05–15.19; P = 0.91]). No other pre-treatment
laboratory parameter predicted the development of an ALT ³
2.5 × ULN after controlling for the cohort effect (Supplemental
Table 1).
Treatment outcomes. There was no association between
maximum drug concentration (Cmax), time to maximum drug
concentration (Tmax), or area under the parasitemia curve at 96
hours post-treatment, for artefenomel or chloroquine, and the
timing or severity of ALT elevations.
Acetaminophen use and alternative medical diagnoses. In
the chloroquine study, the median peak ALT did not differ
between cohort 2 (1.63 × ULN [IQR: 0.82–3.46]), where ibu-
profen was administered for symptom relief, and cohort 3
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(1.39 × ULN [IQR: 1.05–2.5]), where acetaminophen was the
preferred treatment (Supplemental Figure 2). Review of the
source documents did not reveal any alternative causes (in-
cluding exercise) for the observed LFT abnormalities.
Phase IIA study of artefenomel in Thailand. The median
(IQR; range) age of the 41 participants was 26 (21–30; 18–60)
years, and 32 (78%) were male. The mean (range) parasite
count for P. vivax–infected patients was 15,905/μL (5,010–
53,400).25
Themedian ALT increased from 21 IU/L pre-treatment to 30
IU/L at day 7 (P < 0.001). One patient had an ALT elevation
of ³ 2.5 × ULN, with a maximum absolute increase of 156 U/L
(20U/L on day 0, 176U/L on day 7, and improving to 50U/L on
day 15). This patient was treated with a 200 mg dose of arte-
fenomel, the lowest dose used in the study (Figure 3).
Sabah Malaysia. Eighty-five patients had day 0 and day 7
ALTmeasures available andwere included in the analysis. The
median (IQR; range) age was 16 (11–64; 3–65) years, and 63
(74%) were male. The median (IQR) parasite count at day
0 was 4,048/μL (1,523–8,120).
Forty-four (51.8%) of the 85 subjects were treated with
artesunate/mefloquine, 32 (37.7%) with chloroquine, 7 (8.2%)
with artemether/lumefantrine and primaquine, and 2 (2.4%)
with chloroquine and primaquine. Among those treated with
chloroquine, themedian ALTdecreased from14 (IQR: 7–29) at
day 0 to 7.5 (IQR: 5–11) at day 7 (P < 0.001), whereas in those
treated with artemether/lumefantrine, the median ALT de-
creased from17 (IQR: 11–35) at day 0 to 10 (IQR: 7–13) at day7
(P < 0.001). No patient developed an ALT ³ 2.5 × ULN
(Figure 4).
DISCUSSION
Asymptomatic transaminase elevations³2.5 ×ULNwithout
concomitant increases in bilirubin occurred in 11/32 (34%)
subjects in the two P. vivax IBSM studies. Abnormalities
generally began 3 days post-treatment, peaking 5–8 days
post-treatment, with resolution before the EOS. PeakALTwas
typically greater than peak AST. We were unable to identify a
single factor that accounted for all the observed transaminase
elevations in the P. vivax IBSM studies. Moreover, we did not
identify any pre-treatment parameter that predicted sub-
sequent development of transaminase elevations. However,
we observed statistically significant associations between
transaminase elevations and PCB and CRP.
Transaminase elevationsmirroring thoseseen in theP. vivax
IBSM studies were rare in the clinical P. vivax studies, occur-
ring in only 1/41 (2.4%) Thai patients treated with artefenomel
FIGURE 1. Courseof ALTover time inPlasmodiumvivax–inducedblood-stagemalaria.Changes inALT levels over time for all 32 subjects. Eachof
the 32 subjects are represented by a single trace. Day 0 represents the day of inoculation (arrow). Those subjects represented by dotted lines were
from chloroquine cohort C1 (n = 8), and all were treated 8 days post-inoculation. The dashed line represents subject C13 (R013) from chloroquine
cohort C2 who was the only subject treated on day 9 post–inoculation. The ULN for ALT in male subjects (40 IU/L) has been included for reference
(dashed horizontal line). ALT = alanine transaminase; ULN = upper limit of normal.
FIGURE 2. Peak ALT × ULN for each induced blood-stage malaria
subject per treatment. Peak ALT × ULN with median and interquartile
range for subjects treatedwith artefenomel (n=8) and chloroquine (n=
24). Subjects treated with chloroquine came from three cohorts (co-
hort 1, n = 8; cohort 2, n = 8; cohort 3, n = 8). ALT = alanine trans-
aminase; ULN = upper limit of normal.
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and in none of the 76 Malaysian patients treated with chloro-
quine or artemisinin combination therapy. Consistent with
these findings, in a previous phase II study of artefenomel
(800mg) in combination with piperaquine (640mg, 960mg, or
1,440 mg) for treatment of P. falciparum malaria, only 1/448
(0.2%) subjects experienced a grade 3 (5.1–10 × ULN) trans-
aminase elevation.26 Transaminase elevations were also not
observed in a phase I study of artefenomel in 26 healthy vol-
unteers without malaria.23
In the VISs, although the risk of developing elevations of
ALT ³ 2.5 × ULN was higher among subjects treated with
artefenomel than that among those treated with chloroquine,
this associationdisappearedwhencorrected for other factors,
notably the parasite clearance burden (Supplemental Table 7).
Of significance, artefenomel has a more rapid parasiticidal
effect than chloroquine.25,26,31
The PCB is a composite of the rate of parasite clearance
(i.e., PCt1/2) and peak parasitemia around the time of treat-
ment, and thus, it represents the biomass of parasites cleared
immediately post-treatment. As such, it distinguishes be-
tween artefenomel (a fast-killing drug) and chloroquine (a
drug with a slower effect on parasite clearance), while still
accounting for the overall reduction in parasite biomass
post–antimalarial treatment (Table 2). Peak parasitemia has
previously been identifiedas a risk factor for LFTabnormalities
in malaria VISs,39 but in our analysis, it had a weaker re-
lationship with peak ALT than PCB.
We have previously reported post-treatment transaminase
elevations of > 5×ULN in 4/6 (66%) subjects in aP. vivax IBSM
study where a different parasite isolate from a different donor
was used. In that study, treatment was also with the fast-
acting drug artemether/lumefantrine,2 and the high proportion
of subjects with LFT abnormalities, in the context of rapid par-
asite clearance and likely high PCB, is consistent with findings
reported here. LFT abnormalities similar to those described in
the P. vivax IBSM studies have been observed in IBSM studies
with P. falciparum 3D716 as well as in P. falciparum studies
where infection was induced by sporozoites.7,15 Therefore, the
observed LFT abnormalities are unlikely to be due to a specific
effect from the species or strain used during these studies nor
the route of infection.
In clinical trials of antimalarials, clinically significant trans-
aminase elevations occurring after treatment have not been
commonly reported. Assessments of liver function during
the day 5–8 window where ALT changes were observed
in the IBSM studies may not have been universally
undertaken.24,40–46 However, evenwhen testing has occurred
5–8 days post-treatment, transaminase elevations mirroring
those observed in P. vivax IBSM studies appear to be un-
common in P. falciparum–infected patients treated with arte-
misinin combination therapies (0.2–7.8%).19,47–53 For example,
in a recent randomized clinical trial in West Africa where four
different artemisinin combination therapies were evaluated in
4,710 patients experiencing 8,640 malaria episodes (7,119
P. falciparum, 146 P. malariae, 31 Plasmodium ovale, and 17
mixed infections), the LFT was undertaken on days 0 (pre-
dose), 3, 7, and28. In this study, LFTchanges resembling those
we report here were rare, being reported after treatment with
any of the four drug combinations in 0.9–3.9% of the 8,640
treatment encounters, and were more commonly seen in
TABLE 2
Summary of parasitemia-related outcomes in induced blood-stage malaria studies
Drug Cohort Median peak parasitemia (parasites/mL), (IQR) Median parasite clearance half-life (hours), (IQR) Median PCB* (IQR)
Artefenomel n = 8 135,103 (69,107–189,959) 3.60 (3.11–4.31) 2.18 (2.13–2.37)
Chloroquine C1 (n = 8) 10,367 (6,399–12,621) 5.48 (4.35–5.68) 0.63 (0.44–0.83)
Chloroquine C2 (n = 8) 65,109 (25,839–130,410) 4.73 (4.23–5.42) 1.16 (0.83–1.39)
Chloroquine C3 (n = 8) 74,243 (50,089–117,483) 5.59 (4.30–6.09) 1.18 (0.95–1.33)
Chloroquine overall n = 24 41,766 (11,923–78,842) 5.28 (4.33–5.73) 0.95 (0.71–1.22)
Total n = 32 57,554 (13,112–117,483) 4.40 (3.86–5.68) 1.16 (0.75–2.09)
IQR = interquartile range; PCB = parasite clearance burden.
* Parasite clearance burden was calculated by subtracting the parasitemia at 24 hours post-treatment initiation from the peak parasitemia on the log10 scale and is reported as a log-fold change.
TABLE 3
Association of explanatory parameters with elevated peak ALT in induced blood-stage malaria
Explanatory parameter
Peak ALT Logistic regression
Logistic regression with fixed
cohort effect
< 2.5 × ULN (n = 21) ³ 2.5 × ULN (n = 11) OR (95% CI) P-value OR (95% CI) P-value
Median parasite clearance
half-life (hours), (IQR)
4.70 (4.12–5.69) 4.36 (3.16–5.40) 0.69 (0.34–1.39) 0.30 1.06 (0.43–2.60) 0.90
Median peak parasitemia
(parasites/mL), (IQR)
45,156 (12,922–78,227) 96,020 (52,370–201,433) 3.72 (0.77–18.03) 0.10 1.78 (0.17–18.72) 0.63
Median parasite clearance
burden (IQR)
0.96 (0.71–1.41) 2.06 (1.15–2.32) 4.28 (1.26–14.59) 0.020 4.04 (0.38–49.84) 0.25
Median maximum temperature
(C), (IQR)
38.4 (37.3–39.1) 38.7 (38.4–39.3) 1.92 (0.78–4.69) 0.15 2.28 (0.65–7.97) 0.20
Median maximum clinical score
(IQR)
4 (2–6) 6 (4–11) 1.19 (0.98–1.45) 0.085 1.09 (0.87–1.37) 0.45
Median maximum C-reactive
protein × ULN (to EOS), (IQR)
5.4 (2.6–9.2) 12.0 (7.2–14.2) 1.43 (1.10–1.86) 0.008 1.45 (1.05–2.01) 0.025
Median lactate dehydrogenase ×
ULN (to EOS), (IQR)
0.96 (0.86–1.08) 1.25 (1.05–1.36) 1.56 (1.08–2.24) 0.017 1.43 (0.94–2.16) 0.093
ALT = alanine transaminase; EOS = end of study; IQR = interquartile range; OR = odds ratio; ULN = upper limit of normal. Odds ratio refer to a 1-unit change in the measure of the explanatory
parameter (e.g., 1C for maximum temperature). Statistically significant P-values < 0.05 are highlighted in bold.
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children < 5 years of age.19 All patients were treated with
artemisinin-based regimens characterized by rapid parasite
clearance, and thus more likely to have a high PCB.
One possible explanation for the lower frequency of
post-treatment increases in ALT in malaria-endemic set-
tings is that there may be a reduced susceptibility to he-
patic injury due to previous exposure to malaria,54 with
resulting modulation of the host immune response.55 This
may also explain why ALT increases post-treatment occur
more often in returned travelers,5,47 in whom most malaria
episodes will be a primary infection. Alternatively, it is also
possible that genetic polymorphisms or other host char-
acteristics such as iron deficiency could influence sus-
ceptibility to transaminase elevations following malaria
treatment.56,57
Higher maximum CRP was associated with an increased
risk of a peak ALT of ³ 2.5 × ULN, suggesting that systemic
inflammation likely contributes to the development of post-
treatment LFT abnormalities in VISs, as previously postu-
lated.39 Rodent malaria studies have suggested that TNF-α
generated during malaria infection and free heme, produced
following rapid hemolysis, act together to induce hepato-
cyte apoptosis and transaminase leakage.58–61 Testing for
additional markers of hemolysis, free heme, and TNFα
would also be worth undertaking in future studies. In addi-
tion to the effects of systemic inflammation and hemolysis,
it is possible, though speculative, that liver injury in primary
infections may also result from killing of P. vivax parasites
potentially sequestered in the liver, as now recognized to
occur in the spleen,62 possibly exacerbating localized he-
patic inflammation.
The relatively small number of subjects in this study limits
statistical power, and a larger dataset would be required for a
more robust multivariable analysis. Differences between co-
horts meant comparisons across cohorts was difficult and
could confound the analysis. In the case of PCB, it is strongly
affected by both the day of treatment and the antimalarial
used. In addition, as it is calculated solely from two data
points, themeasuremay be susceptible to bias and should be
prospectively evaluated in future studies.
Post-treatment LFT changes appear to bemore common in
P. vivax IBSM than natural infection. Although treating physi-
cians should remain vigilant, these changes have to date been
asymptomatic, self-limiting, and not associated with adverse
clinical outcomes. Researchers and pharmaceutical compa-
nies should become familiar with these findings so that the
mechanisms underlying this phenomenon can be better un-
derstood and alternate explanations of the causation of LFT
changes can be considered in the development of antimalar-
ials. LFTondays3, 5, and7post-treatment initiation shouldbe
incorporated, where possible, into the study design of anti-
malarial clinical trials.
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FIGURE 3. Phase IIA artefenomel study: course of ALT levels.
Changes in ALT levels (U/L) over time for all 41 subjects. Day 1 rep-
resents the day 0 pre-treatment value and day 0 represents the first
ALT value post-treatment. Data are displayed in this way to ease the
graphical representation of the data. For ease of interpretation sub-
jects, 2–19 and 1–22 are represented by dotted and dashed lines,
respectively. The ULN for ALT in male and female subjects (40 IU/L)
from the assay used in the study has been included for reference.
ALT = alanine transaminase; ULN = upper limit of normal.
FIGURE 4. Malaysia studies: courseofALT levels.Day0 (pre-treatment)
and day 7 ALT results for all subjects segregated into those who
had an increase in ALT and those who did not. ALT= alanine
transaminase.
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Supplemental Material 
Liver function test abnormalities in induced blood stage Plasmodium vivax malaria: 
supplementary material 
Malaria clinical score 
The malaria clinical score comprises 14 variables (see below), each being graded between 
0 and 3 based on the severity of impairment of the subjects’ activity (0 = absent; 1 = mild, no 
impairment of usual activity; 2 = moderate, no impairment of activities of daily living; 3 = 
severe, activities of daily living impaired). The scores for all 14 variables are then added 
together to give the malaria clinical score.  
• Headache 
• Myalgia (muscle ache) 
• Arthralgia (joint ache) 
•Fatigue/lethargy 
•Malaise (general discomfort/uneasiness) 
• Chills/Shivering/Rigors 
• Sweating/hot spells 
• Anorexia 
• Nausea 
• Vomiting 
• Abdominal discomfort 
• Fever 
• Tachycardia 
• Hypotension
Supplemental Figure 1. Peak ALT vs parasite clearance burden in IBSM. 
 
ALT (alanine transaminase), ULN (upper limit of normal). Relationship between peak ALT 
(log10) and parasite clearance burden (log10) (Pearson’s correlation). 
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Supplemental Figure 2. Peak ALT Chloroquine Cohort C2 (no acetaminophen) vs 
Chloroquine Cohort C3 (with acetaminophen) in IBSM study subjects.  
ALT (alanine transaminase), ULN (upper limit of normal). Peak ALT of subjects in 
Chloroquine cohort C2 (subjects did not receive acetaminophen) compared to subjects in 
Chloroquine cohort C3 (subjects received acetaminophen). Median and IQR peak ALT 
values for subjects in Chloroquine cohort 2 and Chloroquine cohort 3 are demonstrated. 
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Supplemental Table 1. Association of laboratory parameters with elevated peak ALT in 
IBSM. 
Explanatory Variable  
  
Peak ALT Logistic regression Logistic regression with 
fixed cohort effect 2.5 × ULN 2.5 × ULN 
(n = 21) (n = 11) OR (95% CI) p OR (95% CI) p 
Median peak 
parasitemia Pre-
treatment (log10 
parasites/mL), (IQR) 
4.39  
(3.90 - 4.79) 
4.88  
(4.48 - 5.07) 
4.37  
(0.90 - 21.35) 
0.068 2.97 
(0.29 - 30.13) 
0.36 
Median nadir 
Neutrophils × LLN (To 
EOS), (IQR) 
1.14  
(1.07 - 1.34) 
0.94  
(0.81 - 1.3) 
0.10  
(0.006 - 1.68) 
0.11 0.10 
(0.004 - 2.24) 
0.15 
      
Median nadir 
neutrophils × LLN 
(Pre-treatment),  (IQR) 
2.09  
(1.65 - 2.27) 
1.64  
(1.3 - 1.88) 
0.26 
 (0.06 - 1.23) 
0.090 0.17 
(0.023 - 1.23) 
0.080 
Median platelets × LLN 
(To EOS) , (IQR) 
0.97  
(0.84 - 1.07) 
0.83  
(0.73 - 0.85) 
0.001  
(<0.001 - 0.79) 
0.042 <0.001 
(<0.001 - 0.64) 
0.039 
Median nadir platelets × 
LLN (Pre-treatment), 
(IQR) 
1.17  
(0.99 - 1.36) 
1.01  
(0.85 - 1.24) 
0.04  
(<0.001 - 1.47) 
0.079 0.008 
(<0.001 - 2.22) 
0.093 
Median nadir 
lymphocytes × LLN (To 
EOS), (IQR) 
0.85  
(0.61 - 1.04) 
0.64  
(0.54 - 0.73) 
0.01  
(<0.001 - 0.98) 
0.049 0.04 
(<0.001 - 9.08) 
0.24 
Median nadir 
lymphocytes × LLN 
(Pre-treatment), (IQR)  
0.94  
(0.61 - 1.51) 
0.64  
(0.54 - 0.73) 
0.06  
(0.003 - 1.14) 
0.061 0.01 
(<0.001 - 3.13) 
0.12 
Median nadir white cell 
count × LLN (To EOS), 
(IQR) 
1.03  
(0.97 - 1.2) 
0.89  
(0.74 - 1.17) 
0.06  
(0.002 - 2.26) 
0.13 0.003 
(<0.001 - 0.68) 
0.035 
Median nadir white cell 
count × LLN (Pre-
treatment), (IQR) 
1.31  
(1.11 - 1.63) 
0.97  
(0.86 - 1.37) 
0.60  
(0.005 - 0.84) 
0.036 0.02 
(<0.001 - 1.00) 
0.050 
Median CRP × ULN 
(Pre-treatment), (IQR) 
n = 11 n = 5 1.38  
(0.86 - 2.22) 
0.18   
0.60  
(0.2 - 1.6) 
2.6  
(0.8 - 4.8) 
  
Median LDH × ULN 
(Pre-treatment), (IQR) 
0.69  
(0.60 - 0.78) 
0.79  
(0.66 - 0.87) 
1.41  
(0.83 - 2.37) 
0.20 1.04  
(0.56 - 1.96) 
0.90 
Median chloroquine n = 18 n = 6 0.98 
(0.92 - 1.05) 
0.61   
AUC96 (μg/mL  h), 
(IQR) 
59.25  
(50.31 - 69.24) 
58.24  
(50.32 - 67.10) 
1.00 
(0.92 - 1.09) 
0.93 
Median chloroquine 
Cmax  (μg/mL), (IQR) 
1.03  
(0.88 - 1.23) 
0.93 
(0.75 - 1.25) 
0.29 
(0.009 - 10.01) 
0.50 0.89 
(0.01 - 65.69) 
0.96 
Median artefenomel n = 3 n = 5 1.30 
(0.34 - 4.95) 
  0.71   
AUC96 (μg/mL h), 
(IQR) 
4.01  
(2.45 - 4.87) 
3.72  
(3.43 - 4.44) 
  
Median artefenomel 
Cmax (μg/mL), (IQR) 
0.66  
(0.32 - 0.75) 
0.54  
(0.48 - 0.69) 
2.57 
(0.002 - 3589) 
0.80   
ALT (alanine transaminase), CRP (C-reactive Protein), LDH (lactate dehydrogenase), Cmax 
(maximum concentration of drug), AUC96 (area under the curve for drug dose 96 hours after drug 
administration), ULN (upper limit of normal), OR (odds ratio), EOS (end of study). OR refer to a 
1-unit change in the measure of the explanatory parameter (e.g. 1°C for maximum temperature). 
Significant effects and associations (p < 0.05) are highlighted in bold. Continuous measures are 
described with median (IQR). Results from simple binary logistic regression modelling the 
probability of elevated peak ALT (ALT  2.5 ×ULN) are presented (logistic regression) and also 
adjusted for cohort by including a fixed effect for cohort (logistic regression with fixed cohort 
effect).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2.  Inflammatory parameters per cohort in IBSM. 
Cohort Statistical 
measure 
^Maximum 
temperature 
(°C) 
*Maximum 
Clinical 
score 
Peak CRP × 
ULN   (U/L) 
Peak CRP 
Relative to 
baseline 
(U/L) 
Artefenomel  
(n = 8) 
Median 
(IQR) 
n (%) 
raised^* 
39.2  
(38.7 - 39.7) 
8 (100%) 
8.5  
(6.0 - 12.0) 
7 (87.5%) 
11.6  
(8.9 - 13.8) 
58 
 (44.5 - 69.0) 
Chloroquine 
C1  
(n = 8) 
Median 
(IQR) 
n (%) 
raised^* 
37.3 
 (36.8 - 38.1) 
3 (37.5%) 
3.5 
 (0.5 - 4.0) 
0 (0%) 
1.9  
(0.9 - 4.3) 
6.5  
(3.5 - 14.0) 
Chloroquine 
C2 
(n = 8) 
Median 
(IQR) 
n (%) 
raised^* 
38.6  
(38.3 - 38.9) 
7 (87.5%) 
5.0 
 (2.0 - 10.5) 
4 (50.0%) 
9.9  
(5.2 - 12.1) 
35.5  
(26.0 - 51.0) 
Chloroquine 
C3  
(n = 8) 
Median 
(IQR) 
n (%) 
raised^* 
38.7  
(38.5 - 39.6) 
7 (87.5%) 
6.0 
 (4.0 - 6.5) 
5 (62.5%) 
7.8  
(5.5 - 9.3) 
32.5 
 (24.5 - 46.5) 
Overall  
(n = 32)  
Median 
(IQR) 
n (%) 
raised^* 
38.6 
 (38.1 - 39.2) 
25 (78.1%) 
5.5 
 (2.5 - 8.0) 
16 (50.0%) 
7.5  
(4.8 - 11.6) 
35.8  
(14.5 - 54.0) 
CRP (C-reactive Protein), ULN (upper limit of normal), IQR (interquartile range)^Raised 
maximum temperature ≥ 37.5 C, *raised maximum Clinical Score ≥ 6. Maximum values for 
temperature and clinical score within 3 days either side of treatment. 
 
 
 
 
  
 
 
 
 
 
Supplemental Table 3. Pharmacokinetic parameters per cohort in IBSM. 
Identifier 
 
Antimalarial 
Cohort Statistical measure Cmax (μg/mL) AUC96 (μg/mL × h) 
Artefenomel Median (IQR)  0.60 (0.43 - 0.72) 3.86 (3.08 - 4.66) 
Chloroquine C1 Median (IQR)  1.24 (1.11 - 1.46) 66.28 (59.56 - 79.36) 
Chloroquine C2 Median (IQR)  0.88 (0.73 - 1.02) 52.88 (41.48 - 60.37) 
Chloroquine C3  Median (IQR)  0.99 (0.82 - 1.09) 58.24 (48.24 - 64.48) 
Cmax (maximum concentration of drug), AUC96 (area under the curve for drug dose 96 hours 
after drug administration), IQR (interquartile range). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 4. Pain relief medication per cohort in IBSM. 
Identifier Pain relief medication 
Cohort Statistical 
measure 
Total acetaminophen (g) Total ibuprofen (g) 
Artefenomel Median (IQR) 
n (%) positive^ 
3.0 (2.5 - 5.5) 
8 (100%) 
2.0 (1.8 - 3.2) 
8 (100%)  
Chloroquine C1 Median (IQR) 
n (%) positive^ 
- 
- 
1.0 (0 - 2.0) 
5 (62.5%)  
Chloroquine C2 Median (IQR) 
n (%) positive^ 
- 
- 
2.4 (1.5 - 4.6) 
8 (100%)  
Chloroquine C3 median (IQR) 
n (%) positive^ 
8.8 (5.0 - 10.0) 
8 (100%) 
- 
-  
IQR (interquartile range). ^Subject who received pain relief. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 5. Results of backwards stepwise logistic regression for the risk of 
elevated peak ALT in IBSM with PCT1/2 included in all steps of the models.  
Model Measure OR (95% CI) p 
Including 
cohort effect 
PCT1/2 1.81 (0.57 - 5.69) 0.31 
Nadir Platelets × LLN^ 2.79 (1.12 - 6.93) 0.027 
Cohort - ref Artefenomel 1  
Chloroquine C1 0.16 (0.006 - 3.89) 0.26 
Chloroquine C2 0.04 (0.001 - 1.36) 0.075 
Chloroquine C3 0.03 (< 0.001 - 1.15) 0.059 
No cohort effect PCT1/2 0.95 (0.39 - 2.33) 0.92 
Peak CRP (relative to baseline)  1.06 (1.01 - 1.12) 0.013 
CRP (C-reactive Protein), LLN (lower limit of normal), PCT1/2 (parasite clearance half-life) 
OR (odds ratio). ^Effect size (OR and 95% CI) are converted to per 0.1 unit decrease in × 
LLN. The order of variables removed in the model including cohort effect were were burden, 
white cell count, and then Peak CRP relative to baseline. The order of variables removed in 
the model did not include cohort effect were platelets, burden, and then white cell count. 
 
 
 
 
 
 
 
 
Supplemental Table 6. Results of backwards stepwise logistic regression for the risk of 
elevated peak ALT in IBSM with parasite clearance burden included in all steps of the 
models.  
Model Measure OR (95% CI) p 
Including 
cohort effect 
PCB (log10 scale) 3.60 (0.19 - 68.81) 0.40 
Peak CRP (relative to 
baseline)  
1.06 (1.00 - 1.13) 0.044 
Cohort - ref Artefenomel  1  
Chloroquine C1 8.63 (0.026 - 2889) 0.47 
Chloroquine C2 2.89 (0.05 - 153) 0.60 
Chloroquine C3 1.77 (0.03 - 114) 0.79 
No cohort 
effect 
PCB (log10 scale) 1.86 (0.42 - 8.17) 0.41 
Peak CRP (relative to 
baseline) 
1.05 (1.00 - 1.11) 0.054 
CRP (C-reactive Protein), OR (odds ratio), PCB (parasite clearance burden). ^Effect size (OR 
and 95% CI) are converted to per 0.1 unit decrease in × LLN. The order of variables removed 
in the model including cohort effect were PCT1/2, platelets and then white cell count. The 
order of variables removed in the model did not include cohort effect was white cell count, 
PCT1/2 and then platelets.  
 
 
 
 
 
 
 
 
 
 Supplemental Table 7. Logistic regression for the risk of elevated peak ALT in IBSM 
with antimalarial drug, drug and treatment day and drug and parasite clearance 
burden.  
OR (odds ratio), PCB (parasite clearance burden). Risk of ALT ≥ 2.5 × ULN depending on 
drug, drug and treatment day, and drug and parasite clearance burden.  
Model Measure OR (95% CI) p 
Drug  
(n = 32) 
Drug  
Chloroquine Reference  
Artefenomel 5.00 (0.91 - 27.47) 0.064 
Drug and 
Treatment day 
(n = 31) 
Drug  
Chloroquine Reference  
Artefenomel 4.58 (0.73 - 28.65) 0.10 
Treatment Day  
Treatment day 8 Reference  
Treatment day 10 2.55 (0.23 - 27.71) 0.44 
Drug and PCB 
(n = 32) 
Drug type  
Chloroquine Reference  
Artefenomel 0.84 (0.05 - 15.19) 0.91 
PCB (log10 scale) 4.71 (0.61 - 36.41) 0.14 
Supplemental Table 8. Pearson correlation of with peak ALT in IBSM. 
 Clinical measure Correlation  p 
Peak AST 0.99 < 0.001 
Peak Bilirubin  -0.10 0.57 
Peak LDH 0.58 < 0.001 
PCT1/2 -0.26 0.16 
Pre-treatment Peak parasitemia 0.36 0.044 
Overall Peak parasitemia 0.39 0.027 
PCB 0.58 < 0.001 
Nadir Neutrophils -0.09 0.62 
Nadir Platelets -0.26 0.15 
Nadir Lymphocytes -0.41 0.018 
Nadir White cell count -0.03 0.87 
Peak Clinical Score 0.42 0.017 
Maximum Temperature 0.29 0.11 
Peak CRP 0.44 0.012 
ALT (alanine transaminase), AST (aspartate transaminase, LDH (lactate dehydrogenase), 
CRP (C-reactive Protein), LDH (lactate dehydrogenase), PCT1/2 (parasite clearance half-life), 
PCB (parasite clearance burden). LFT and haematology results are in units of overall 
peak/minimum times ULN or LLN. effects and associations (p < 0.05) are highlighted in 
bold. 
